Dysregulation of intracellular copper homeostasis is common to transgenic mice expressing human mutant superoxide dismutase-1s regardless of their copper-binding abilities

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 308-319

  Tokuda, Eiichi ^a   Okawa, Eriko ^b   Watanabe, Shunsuke ^b   Ono, Shin Ichi ^b,c   Marklund, Stefan L ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b NIHON UNIVERSITY   (Japan)

^c Akiru Municipal Medical Center   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Copper homeostasis; Superoxide dismutase 1; Tetrathiomolybdate

Indexed keywords

ALUMINUM; CALCIUM; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; IRON; MAGNESIUM; MANGANESE; TETRATHIOMOLYBDATE AMMONIUM; ZINC;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; COPPER METABOLISM; ENZYME ACTIVE SITE; FEMALE; GASTROCNEMIUS MUSCLE; GLIOSIS; LUMBAR SPINAL CORD; MOTONEURON; MOUSE; MUSCLE ATROPHY; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SURVIVAL TIME; TRANSGENIC MOUSE; VENTRAL ROOT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CHELATING AGENTS; COPPER; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; MOLYBDENUM; MOTOR NEURONS; MUTATION; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84876336692     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.01.001     Document Type: Article

References (71)

1. Ahtoniemi T., et al. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007, 71:30-37.
2. Alexander G.M., et al. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Mol. Brain Res. 2004, 130:7-15.
3. Alvarez H.M., et al. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science 2010, 327:331-334.
4. Andersen P.M., Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat. Rev. Neurol. 2011, 7:603-615.
5. Andreassen O.A., et al. Effects of an inhibitor of poly (ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. 2001, 168:419-424.
6. Banci L., et al. Affinity gradients driver copper to cellular destinations. Nature 2010, 465:645-648.
7. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13.
8. Bergemalm D., et al. Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. J. Neurosci. 2006, 26:4147-4154.
9. Boillée S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
10. Brewer G.J. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin. Investig. Drugs 2009, 18:89-97.
11. Bruijn L.I., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progression disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
12. Davies N.T. Recent studies of antagonistic interactions in the aetiology of trace element deficiency and excess. Proc. Nutr. Soc. 1974, 33:293-298.
13. Durazo A., et al. Metal-free superoxide dismutase-1 and three different amyotrophic lateral sclerosis variants share a similar partially unfolded beta-barrel at physiological temperature. J. Biol. Chem. 2009, 284:34382-34389.
14. Ferraiuolo L., et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 11:616-630.
15. Forsberg K., et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010, 5:e11552.
16. Friese A., et al. Gamma and alpha motor neurons distinguished by expression of transcription factor Err3. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13588-13593.
17. Furukawa Y., et al. Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS. EMBO J. 2004, 23:2872-2881.
18. Furukawa Y., et al. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 2008, 283:24167-24176.
19. Gellein K., et al. Concentrations of Cd, Co, Cu, Fe, Mn, Rb, V, and Zn in formalin-fixed brain tissue in amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam determined by high-resolution ICP-MS. Biol. Trace Elem. Res. 2003, 96:39-60.
20. Gong Y.H., Elliott J.L. Metallothionein expression is altered in a transgenic murine model of familial amyotrophic lateral sclerosis. Exp. Neurol. 2000, 162:27-36.
21. Goto J.J., et al. Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 2000, 275:1007-1014.
22. Gould T.W., et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 2006, 26:8774-8786.
23. Graffmo K.S., et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013, 22:51-60.
24. Grosskreutz J., et al. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 2010, 47:165-174.
25. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
26. Gurney M.E., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996, 39:147-157.
27. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
28. Hayward L.J., et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 2002, 277:15923-15931.
29. Heiman-Patterson T.D., et al. Effect of genetic background on phenotype variability in transgenic mouse model of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler. 2011, 12:79-86.
30. Hottinger A.F., et al. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 1997, 9:1548-1551.
31. Ischiropoulos H., et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298:431-437.
32. Jaarsma D., et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 2000, 7:623-643.
33. Jeong S.Y., et al. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2009, 29:610-619.
34. Jonsson P.A., et al. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain 2004, 127:73-88.
35. Jonsson P.A., et al. Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J. Neuropathol. Exp. Neurol. 2006, 65:1126-1136.
36. Jonsson P.A., et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006, 129:451-464.
37. Kawamata T., et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140:691-707.
38. Kiaei M., et al. Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004, 24:7945-7950.
39. Lelie H.L., et al. Copper and zinc metallation status of copper-zinc superoxide dismutase from amyotrophic lateral sclerosis transgenic mice. J. Biol. Chem. 2011, 286:2795-2806.
40. Li Q.X., et al. Overexpression of Aβ is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell 2006, 5:153-165.
41. Liao B., et al. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012, 237:147-152.
42. Ludolph A.C., et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph. Lateral Scler. 2007, 8:217-223.
43. Lutsenko S., et al. Copper handling machinery of the brain. Metallomics 2010, 2:596-608.
44. Marklund S.L. Spectrophotometric study of spontaneous disproportionation of superoxide anion radical and sensitive direct assay for speroxide dismutase. J. Biol. Chem. 1976, 251:7504-7507.
45. Marklund S.L., et al. Normal binding and reactivity of copper in mutant superoxide dismutase isolated from amyotrophic lateral sclerosis patients. J. Neurochem. 1997, 69:675-681.
46. Nagano S., et al. Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur. J. Neurosci. 2001, 7:1363-1370.
47. Nagano S., et al. The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp. Neurol. 2003, 179:176-180.
48. G93A mouse, a model of amyotrophic lateral sclerosis. Neuropharmacology 2011, 60:1200-1208.
49. Ogawa Y., et al. Stability of mutant superoxide dismutase-1 associated with familial amyotrophic lateral sclerosis determines the manner of copper release and induction of thioredoxin in erythrocytes. Biochem. Biophys. Res. Commun. 1997, 241:251-257.
50. Prudencio M., et al. A novel variant of human SOD1 harboring ALS-associated and experimental mutations in metal-binding residues and free cysteines lacks toxicity in vivo. J. Neurochem. 2012, 121:475-485.
51. Puttaparthi K., et al. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J. Neurosci. 2002, 22:8790-8796.
52. Reaume A.G., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996, 13:43-47.
53. Rhoads T.W., et al. Measuring copper and zinc superoxide dismutase from spinal cord tissue using electrospray mass spectrometry. Anal. Biochem. 2011, 415:52-58.
54. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
55. Rouaux C., et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007, 27:5535-5545.
56. Scott S., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008, 9:4-15.
57. Stillman M.J., et al. A luminescence probe for metallothionein in liver tissue: emission intensity measured directly from copper metallothionein induced in rat liver. FEBS Lett. 1989, 257:283-286.
58. Subramaniam J.R., et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 2002, 5:301-307.
59. Tiwari A., et al. Metal deficiency increases aberrant hydrophobicity of mutant superoxide dismutases that cause amyotrophic lateral sclerosis. J. Biol. Chem. 2009, 284:27746-27758.
60. Tokuda E., et al. Metallothionein proteins, copper and zinc concentrations, and lipid peroxidation level in rodent model for amyotrophic lateral sclerosis. Toxicology 2007, 229:33-41.
61. Tokuda E., et al. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slow progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp. Neurol. 2008, 213:122-128.
62. Tokuda E., et al. Dysregulation of intracellular copper homeostasis in a mouse model of mutant copper/zinc superoxide dismutase-linked familial amyotrophic lateral sclerosis. J. Neurochem. 2009, 111:181-191.
63. Wang J., et al. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 2002, 10:128-138.
64. Wang J., et al. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum. Mol. Genet. 2003, 12:2753-2764.
65. Wang J., et al. Disease-associated mutations at copper ligand histidine residues of superoxide dismutase 1 diminish the binding of copper and compromise dimer stability. J. Biol. Chem. 2007, 282:345-352.
66. Wang L., et al. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol. Dis. 2009, 35:234-240.
67. West A.K., et al. Metallothionein in the central nervous system: roles in protection, regeneration and cognition. Neurotoxicology 2008, 29:489-503.
68. Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010, 19:2284-2302.
69. Wroe R., et al. ALSOD: the Amyotrophic lateral sclerosis online database. Amyotroph. Lateral Scler. 2008, 9:249-250.
70. Zetterström P., et al. Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14157-14162.
71. Zheng Z., et al. Altered microglial copper homeostasis in a mouse model of Alzheimer's disease. J. Neurochem. 2010, 114:1630-1638.